OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Gabriel Vargas

1 Projects | 1 Researchers | $5,814,712 Invested

2023

Curasen Therapeutics Inc.

Gabriel Vargas, MD PhD

CST-3056 - CNS Optimized α1A-AR Partial Agonist Proposal for AD and Related Diseases

  • Funding Amount: $5,814,712
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Other
  • Status: Active